title: Insulin sensitivity in patients with essential hypertension: no influence of the ACE inhibitor enalapril.
abstract: We studied the effect of an ACE inhibitor (Enalapril [ENA], 10 mg o.d.) and a calcium-channel blocker (Nitrendipine [NIT], 20 mg o.d.) on insulin sensitivity in a double-blind cross-over study. Insulin sensitivity was measured by a two-step hyperinsulinemic euglycemic clamp. Serum potassium concentrations were kept constant during the clamp procedure by means of a variable potassium infusion. Twenty patients with essential hypertension (age 35+/-12 years [mean+/-SD], BMI 31.9+/-5.0 kg m2, initial blood pressure 152+/-10/99+/-6 mmHg) were treated with ENA or NIT for 4 weeks, respectively, with a wash-out period of 3 weeks. No carry-over effects or period effects were observed. Both drugs induced a comparable decline in systolic and diastolic blood pressure (ENA - 15+/-9/ - 13+/-8 mmHg, NIT -16+/-8/- 12+/-6 mmHg). No significant change in body weight occurred with both treatments (ENA -0.4+/-2.0; NIT 0.6+/-1.1 kg). Neither drug had a significant impact on any parameter of insulin sensitivity measured (e.g. insulin sensitivity index SI: ENA 5.2+/-2.0 [basal 5.1+/-2.2], NIT 5.8+/-3.0 [basal SI 5.1+/-2.4) mi/min x m2/microU/ml). In conclusion, no significant differences between ENA and NIT on insulin sensitivity were observed. The reduction of blood pressure had no apparent effect on insulin sensitivity.
authors.affiliation: Department of Metabolic Diseases and Nutrition, WHO Collaborating Center for Diabetes, Heinrich-Heine-University, Düsseldorf, Germany. tim.heise@uni-duesseldorf.de
authors.forename: T
authors.initials: T
authors.lastname: Heise
authors.forename: L
authors.initials: L
authors.lastname: Heinemann
authors.forename: K
authors.initials: K
authors.lastname: Kristahn
authors.forename: M
authors.initials: M
authors.lastname: Berger
authors.forename: P T
authors.initials: PT
authors.lastname: Sawicki
mesh_terms: D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004656:Enalapril / Q000494:pharmacology*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism; D007328:Insulin / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009568:Nitrendipine / Q000494:pharmacology; D011188:Potassium / Q000097:blood
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D007328:Insulin; D004656:Enalapril; D009568:Nitrendipine; D011188:Potassium